{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:05:52Z","timestamp":1791295552471,"version":"4.1.0"},"reference-count":48,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2009,5,26]],"date-time":"2009-05-26T00:00:00Z","timestamp":1243296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The first formal classification of chronic myeloid neoplasms is credited to William Dameshek, who in 1951 described the concept of \u201cmyeloproliferative disorders (MPD)\u201d by grouping together chronic myelogenous leukemia, polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2001 World Health Organization (WHO) classification of myeloid malignancies included these MPDs under the broader category of chronic myeloproliferative diseases (CMPD), which also included chronic neutrophilic leukemia, chronic eosinophilic leukemia\/hypereosinophilic syndrome (CEL\/HES), and \u201cCMPD, unclassifiable.\u201d The revised 2008 WHO classification system featured the following changes: 1) the term \u201cCMPD\u201d was replaced by \u201cmyeloproliferative neoplasm (MPN),\u201d 2) mast cell disease was formally included under the category of MPN, and 3) the subcategory of CEL\/HES was reorganized into \u201cCEL not otherwise specified (CEL\u2010NOS)\u201d and \u201cmyeloid and lymphoid neoplasms with eosinophilia and abnormalities of <jats:italic>PDGFRA, PDGFRB<\/jats:italic>, and <jats:italic>FGFR1<\/jats:italic>\u201d; CEL\u2010NOS remained a subcategory of \u201cMPN,\u201d whereas the latter neoplasms were now assigned a new category of their own. Furthermore, diagnostic criteria for PV, ET, and PMF were revised by incorporating recently described molecular markers (eg, <jats:italic>JAK2<\/jats:italic> and <jats:italic>MPL<\/jats:italic> mutations) as well as underscoring the role of histology in differentiating reactive from clonal myeloproliferations. As a result, red cell mass measurement is no longer necessary for the diagnosis of PV, and ET can now be diagnosed at a lower platelet count threshold. The revised WHO document continues to promote the recognition of histologic categories as a necessary first step toward the genetic characterization of myeloid malignancies. Cancer 2009. \u00a9 2009 American Cancer Society.<\/jats:p>","DOI":"10.1002\/cncr.24440","type":"journal-article","created":{"date-parts":[[2009,5,26]],"date-time":"2009-05-26T22:53:48Z","timestamp":1243378428000},"page":"3842-3847","source":"Crossref","is-referenced-by-count":188,"title":["The 2008 World Health Organization classification system for myeloproliferative neoplasms"],"prefix":"10.1002","volume":"115","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Vardiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,5,26]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"17","volume-title":"World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues","author":"Vardiman JW","year":"2001"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404955"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2008.02.004"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.119"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404946"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1041130409"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.4161\/cc.6.5.3919"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06038.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.23.10560"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000046639"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.162"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-018879"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404810"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065202"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083501"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400934"},{"key":"e_1_2_6_23_2","first-page":"871","article-title":"FIP1L1\u2010PDGFRA and c\u2010kit D816V mutation\u2010based clonality studies in systemic mast cell disease associated with eosinophilia","volume":"89","author":"Tefferi A","year":"2004","journal-title":"Haematologica."},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa025217"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0787"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90322-0"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0198-84"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020150"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1627"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0006"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404977"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1199"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000101706"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2005.07.015"},{"key":"e_1_2_6_35_2","first-page":"183","article-title":"Polycythemia Vera Study Group: a historical perspective","volume":"23","author":"Wasserman LR","year":"1986","journal-title":"Semin Hematol."},{"key":"e_1_2_6_36_2","first-page":"483","article-title":"The treatment of polycythemia. A panel discussion","volume":"32","author":"Wasserman LR","year":"1968","journal-title":"Blood."},{"key":"e_1_2_6_37_2","first-page":"177","article-title":"Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group","volume":"23","author":"Murphy S","year":"1986","journal-title":"Semin Hematol."},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1183"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404373"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.4065\/82.5.599"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05764.x"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05776.x"},{"key":"e_1_2_6_43_2","first-page":"355","article-title":"Hematopathologic findings in the myeloproliferative disorders","volume":"22","author":"Dickstein JI","year":"1995","journal-title":"Semin Oncol."},{"key":"e_1_2_6_44_2","first-page":"429","article-title":"Primary myelofibrosis\u2010osteomyelosclerosis (agnogenic myeloid metaplasia): correlation of clinical findings with bone marrow histopathology and prognosis","volume":"9","author":"Thiele J","year":"1989","journal-title":"Anticancer Res."},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00529.x"},{"key":"e_1_2_6_46_2","first-page":"368","article-title":"The value of bone marrow histology in differentiating between early stage Polycythemia vera and secondary (reactive) Polycythemias","volume":"86","author":"Thiele J","year":"2001","journal-title":"Haematologica."},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21183"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2210"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404948"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24440","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:25:44Z","timestamp":1760268344000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24440"}},"subtitle":["Order out of chaos"],"short-title":[],"issued":{"date-parts":[[2009,5,26]]},"references-count":48,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1002\/cncr.24440"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24440","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,26]]}}}